Loading stock data…
HALO
$71.48+0.75 (+1.06%)
After Hours$71.25-0.23 (-0.32%)· Last close Jun 9
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Halozyme Therapeutics, Inc. in the Healthcare sector is trading at $71.48 with a market capitalization of $8.3B. Wall Street consensus targets $83.90 (10 analysts), implying a +17.4% move over the next 12 months. The stock is currently 13% below its 52-week high of $82.22, remaining 3.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +17.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$71.48
Potential Downside
3.4%
Whystock Fair Value$69.03
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$83.90+17.4%
Range$57.00 – $96.00
Fundamentals
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the pate...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.50
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
158.83%
Volume
Today's trading volume
1.32M
Recent News
How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story
In recent days, Halozyme Therapeutics’ partner argenx reported positive new data for a therapy using Halozyme’s ENHANZE® drug delivery technology, while an analyst reaffirmed a positive rating on the company. This combination of external clinical validation and continued analyst support underscores how Halozyme’s business model is closely tied to partner success with its core platform. We’ll now examine how this fresh validation of ENHANZE® could influence Halozyme’s existing investment...
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today
Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 5.2% in the afternoon session after an analyst reiterated a Buy rating on the stock, and a partner company, argenx, presented positive new data for a drug that utilizes Halozyme's technology.
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.